ABSENCE OF CORRELATIONS AMONG 3 PUTATIVE IN-VIVO PROBES OF HUMAN CYTOCHROME-P4503A ACTIVITY IN YOUNG HEALTHY-MEN

被引:132
作者
KINIRONS, MT
OSHEA, D
DOWNING, TE
FITZWILLIAM, AT
JOELLENBECK, L
GROOPMAN, JD
WILKINSON, GR
WOOD, AJJ
机构
[1] VANDERBILT UNIV, MED CTR, SCH MED, DIV CLIN PHARMACOL, NASHVILLE, TN 37232 USA
[2] JOHNS HOPKINS UNIV, DEPT ENVIRONM & HLTH SCI, BALTIMORE, MD 21218 USA
关键词
D O I
10.1038/clpt.1993.199
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In vitro studies with human liver microsomes have shown that erythromycin N-demethylation, dapsone N-hydroxylation, and the 60-hydroxylation of cortisol are all primarily mediated by P4503A4. Trait measurements to assess the in vivo level of activity of these separate oxidations have also been developed previously. This study investigated the relationships among the three phenotypic trait measurements in 30 young healthy white men. The frequency distributions of the trait values were all unimodal, with a twofold range for the erythromycin breath test and the urinary dapsone recovery ratio; the urinary 6beta-hydroxycortisol/cortisol ratio was more variable, with a 17-fold range of values. No statistically significant correlations were observed among any of the trait measurements (dapsone recovery ratio versus erythromycin breath test: r = -0.07, p = 0.7; urinary 6beta-hydroxycortisol/cortisol ratio versus erythromycin breath test: r = -0.12, p = 0.6; urinary 6beta-hydroxycortisol/cortisol ratio versus dapsone recovery ratio: r = 0.13, p = 0.5. This lack of any relationship was unexpected and the reason(s) is unknown; however, it is possible that factors such as route of administration and extrahepatic metabolism in the intestinal epithelium and kidney are involved. Further studies are required to identify and validate the use of an appropriate in vivo probe of P4503A4 in humans.
引用
收藏
页码:621 / 629
页数:9
相关论文
共 46 条
  • [1] LIDOCAINE METABOLISM IN HUMAN-LIVER MICROSOMES BY CYTOCHROME-P450IIIA4
    BARGETZI, MJ
    AOYAMA, T
    GONZALEZ, FJ
    MEYER, UA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (05) : 521 - 527
  • [2] BIENVENU T, 1991, INT J CLIN PHARM TH, V29, P441
  • [3] COMBALBERT J, 1989, DRUG METAB DISPOS, V17, P197
  • [4] THE GENETIC-POLYMORPHISM OF DEBRISOQUINE SPARTEINE METABOLISM - CLINICAL ASPECTS
    EICHELBAUM, M
    GROSS, AS
    [J]. PHARMACOLOGY & THERAPEUTICS, 1990, 46 (03) : 377 - 394
  • [5] FLEMING CM, 1992, MOL PHARMACOL, V41, P975
  • [6] THE INCREASE IN URINARY-EXCRETION OF 6-BETA-HYDROXYCORTISOL AS A MARKER OF HUMAN HEPATIC CYTOCHROME-P450IIIA INDUCTION
    GED, C
    ROUILLON, JM
    PICHARD, L
    COMBALBERT, J
    BRESSOT, N
    BORIES, P
    MICHEL, H
    BEAUNE, P
    MAUREL, P
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (04) : 373 - 387
  • [7] OXIDATION OF DIHYDROPYRIDINE CALCIUM-CHANNEL BLOCKERS AND ANALOGS BY HUMAN LIVER CYTOCHROME-P-450 IIIA4
    GUENGERICH, FP
    BRIAN, WR
    IWASAKI, M
    SARI, MA
    BAARNHIELM, C
    BERNTSSON, P
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (06) : 1838 - 1844
  • [8] GUENGERICH FP, 1986, MOL PHARMACOL, V30, P287
  • [9] GUENGERICH FP, 1991, J PHARMACOL EXP THER, V256, P1189
  • [10] ABSENCE OF CYP3A GENETIC-POLYMORPHISM ASSESSED BY URINARY-EXCRETION OF 6-BETA-HYDROXYCORTISOL IN 102 HEALTHY-SUBJECTS ON RIFAMPICIN
    HORSMANS, Y
    DESAGER, JP
    HARVENGT, C
    [J]. PHARMACOLOGY & TOXICOLOGY, 1992, 71 (04): : 258 - 261